{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.99","upperLimit":"57.36","value":"24.9"},{"groupId":"OG001","lowerLimit":"3.02","upperLimit":"13.93","value":"3.6"},{"comment":"1 participant only experienced CR","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"8.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"description":"Duration of complete response (CR) defined as the time from when the criteria are first met for CR+CRc (whichever was recorded first) until the date that the criteria for relapse after CR+CRc are met, according to the previously reported criteria for CR and CRc and following criteria of relapse after CR+CRc (Cheson BD et al. J Clin Oncol 2007;25:579-586.):\n\nMarrow: blast percentage \\>5% (if no peripheral blasts, then confirmation aspirate required ≥ 1week later)\n\nPeripheral blood: presence of leukemic blasts\n\nSkin: increase in skin score greater than the sum of nadir plus 50% baseline score\n\nNodal masses: appearance of a new lesion(s) \\>1.5 cm in any axis, ≥50% increase from nadir in SPD of more than one node, or ≥50% increase from nadir in longest diameter of a previously identified node \\>1cm in short axis\n\nSpleen, liver: \\>50% increase from nadir in the SPD of any previous lesions","dispersionType":"Full Range","groups":[{"description":"First-Line BPDCN patients enrolled across stages","id":"OG000","title":"First-Line BPDCN"},{"description":"R/R BPDCN enrolled across stages","id":"OG001","title":"R/R BPDCN"},{"description":"AML patients enrolled in stages 1 and 2","id":"OG002","title":"Acute Myeloid Leukemia"}],"paramType":"MEDIAN","populationDescription":"Efficacy population including evaluable patients treated at 12 μg/kg/day in the first-line BPDCN, R/R BPDCN and AML","reportingStatus":"POSTED","timeFrame":"at pre-defined treatment cycle intervals from randomization up to disease progression, up to 5 years","title":"Duration of CR in First-line BPDCN, R/R BPDCN and AML","type":"SECONDARY","unitOfMeasure":"months"}